These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32042194)

  • 21. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
    Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
    Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.
    Wang G; Wu M; Durham AC; Radaelli E; Mason NJ; Xu X; Roth DB
    PLoS One; 2020; 15(3):e0229728. PubMed ID: 32210430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
    Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
    Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients.
    Wong S; Ehrhart EJ; Stewart S; Zismann V; Cawley J; Halperin R; Briones N; Richter K; Sivaprakasam K; Perdigones N; Contente-Cuomo T; Facista S; Trent JM; Murtaza M; Khanna C; Hendricks WPD
    PLoS One; 2022; 17(7):e0264986. PubMed ID: 35867969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A patient-researcher partnership for rare cancer research.
    Staniszewka S
    Nat Med; 2020 Feb; 26(2):164-165. PubMed ID: 32042195
    [No Abstract]   [Full Text] [Related]  

  • 32. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
    Italiano A; Chen CL; Thomas R; Breen M; Bonnet F; Sevenet N; Longy M; Maki RG; Coindre JM; Antonescu CR
    Cancer; 2012 Dec; 118(23):5878-87. PubMed ID: 22648906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
    Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Monitoring of a Patient with Synchronous Metastatic Angiosarcoma and Breast Cancer Using ctDNA.
    Vannas C; Escobar M; Österlund T; Andersson D; Mouhanna P; Soomägi A; Molin C; Wennergren D; Fagman H; Ståhlberg A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
    Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
    Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation of the PTEN gene in a human hepatic angiosarcoma.
    Tate G; Suzuki T; Mitsuya T
    Cancer Genet Cytogenet; 2007 Oct; 178(2):160-2. PubMed ID: 17954274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
    Moon WK; Chen HH; Shin SU; Han W; Chang RF
    Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.
    Chen HB; Gong XY; Li W; Chen DS; Zhao LL; Li S; Xiao MZ; Cheng L; Chen X
    Oral Oncol; 2021 Oct; 121():105436. PubMed ID: 34371452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.